U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT06806592) titled 'A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases' on Jan. 28.
Brief Summary: Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study. People can only take part if they show no improvement in lung function after standard treatment with immunosuppressant medicine. The main purpose of this study is to find out how a medicine called nerandomilast affects the lungs in people with systemic autoimmune rheumatic disease.
Participants are put into 2 groups randomly, which means by chance. One group t...